ASX Futures down 30 points as overseas and domestic news takes its toll

Published 08-JUL-2020 09:19 A.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

It was a rollercoaster ride for the S&P/ASX 200 index (XJO) on Tuesday as it started strongly before dipping around midday, rallying mid-afternoon and then falling some 50 points in the last hour of trading.

However, the final close of 6013 points was only down marginally on the previous day, and it could be argued that this was a good result given negative sentiment that emerged in the afternoon could mainly be attributed to coronavirus news.

There is now a second wave of economic turmoil to be factored into company forecasts and the broader Australian economy, and further downside wouldn’t surprise.

Adding further fuel to the fire on Wednesday will be the poor performance of overseas markets.

The ASX SPI200 index is down 30 points to 5959 points.

24 hours

Asian markets gave up some of the previous day’s gains yesterday with the Hang Seng hardest hit as it fell 1.4% or 363 points to close at 25,975 points.

The Nikkei 225 shed 100 points or 0.4%, closing at 22,614 points.

The Shanghai Composite bucked the trend, adding to the previous day’s strong gains by another 0.4% to close at 3345 points.

The FTSE 100 started the day in negative territory and continued the downhill slide in afternoon trading, closing at 6190 points, down 1.5%.

Negative sentiment also prevailed in mainland European markets with the DAX down nearly 1% or 116 points to 12,617 points.

The CAC 40 came off 0.7% or 38 points, closing at 5043 points.

Moving to the US, the Dow was the hardest hit index, sliding 1.5% or nearly 400 points to close at 25,890 points.

The S&P 500 was down 1.1% to 3145 points.

Even the NASDAQ couldn’t save the day as it fell 0.9% or 90 points to close at 10,343 points.

It is worth noting though that earlier in the session the index made a new all-time high of 10,519 points.

Many of the negative signs appear to be re-emerging with the CBOE Volatility Index increasing from about 27.5 points to 29.5 points.

There was a flock to gold as it spiked from about US$1785 per ounce to close near its high of US$1811 per ounce.

After pushing up towards US$0.70, the Australian dollar is starting to show some weakness.

This could well be linked to the re-emergence of COVID concerns, suggesting there could be further downside to come.

This would benefit Australian mining companies - based on the current gold price and an Australian dollar of US$0.69 the prevailing Australian dollar gold price is about $2620 per ounce, representing a margin of around $1300 per ounce relative to average production costs of $1300 per ounce.

It was a fairly flat performance for the Brent Crude Oil Continuous Contract as it finished the day at US$43 per barrel.

The iron ore price continued to track north, gaining a hefty 1.7% to US$103 per tonne.

Base metals took a breather after some strong gains in recent days.

However, lead is one to watch as it broke through the US$0.81 per pound mark to hit a near four-month high.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free